Literature DB >> 18931895

Disease rarity, carrier status, and gender: a triple disadvantage for women with Fabry disease.

Andrea L Gibas1, Regan Klatt, Jack Johnson, Joe T R Clarke, Joel Katz.   

Abstract

Fabry disease is a multi-systemic X-linked genetic disorder which has progressive and deadly consequences for those it afflicts. Fabry disease symptoms are widely recognized as a substantive burden for affected males. In comparison, female heterozygotes have traditionally been viewed as relatively symptom-free, though a debate continues about whether and how much they suffer with the disease. Previous research suggests that females with Fabry disease may be triply disadvantaged in healthcare settings owing to: (1) disease rarity, (2) devalued carrier status, and (3) gender. The combined effects of these three factors suggest that female heterozygotes may suffer substantially with Fabry disease symptoms. A qualitative analysis of a brief disease-specific questionnaire provides supportive evidence. The female Fabry disease participants described experiencing significant symptoms that interfered with their lives. They also described unsatisfying experiences with healthcare professionals related to disease rarity, carrier status, and gender. The results of this study corroborate the suggestion that this triple disadvantage exists and may preclude appropriate management and treatment of females with Fabry disease. The role of healthcare professionals, including genetic counselors, in remedying this disadvantage is reviewed.

Entities:  

Mesh:

Year:  2008        PMID: 18931895     DOI: 10.1007/s10897-008-9179-7

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  28 in total

1.  Pain in Anderson-Fabry's disease.

Authors:  M M Chowdhury; P J Holt
Journal:  Lancet       Date:  2001-03-17       Impact factor: 79.321

2.  Angiokeratoma and pain, but not Fabry's disease: considerations for differential diagnosis.

Authors:  M Ries; K Wendrich; C Whybra; C Kampmann; A Gal; M Beck
Journal:  Contrib Nephrol       Date:  2001       Impact factor: 1.580

3.  The art and science of clinical knowledge: evidence beyond measures and numbers.

Authors:  K Malterud
Journal:  Lancet       Date:  2001-08-04       Impact factor: 79.321

4.  Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.

Authors:  K D MacDermot; A Holmes; A H Miners
Journal:  J Med Genet       Date:  2001-11       Impact factor: 6.318

5.  A survey of the pain experienced by males and females with Fabry disease.

Authors:  Andrea L Gibas; Regan Klatt; Jack Johnson; Joe T R Clarke; Joel Katz
Journal:  Pain Res Manag       Date:  2006       Impact factor: 3.037

6.  Fabry's disease on the mechanism of the peripheral nerve involvement.

Authors:  N Fukuhara; M Suzuki; N Fujita; T Tsubaki
Journal:  Acta Neuropathol       Date:  1975-10-27       Impact factor: 17.088

7.  Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Authors:  R Schiffmann; J B Kopp; H A Austin; S Sabnis; D F Moore; T Weibel; J E Balow; R O Brady
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

8.  Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.

Authors:  F Baehner; C Kampmann; C Whybra; E Miebach; C M Wiethoff; M Beck
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

9.  Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.

Authors:  A Mehta; R Ricci; U Widmer; F Dehout; A Garcia de Lorenzo; C Kampmann; A Linhart; G Sunder-Plassmann; M Ries; M Beck
Journal:  Eur J Clin Invest       Date:  2004-03       Impact factor: 4.686

Review 10.  Comparative evaluation of alpha-galactosidase A infusions for treatment of Fabry disease.

Authors:  Robert J Hopkin; John Bissler; Gregory A Grabowski
Journal:  Genet Med       Date:  2003 May-Jun       Impact factor: 8.822

View more
  10 in total

1.  A novel unbiased method reveals progressive podocyte globotriaosylceramide accumulation and loss with age in females with Fabry disease.

Authors:  Behzad Najafian; Aurelio Silvestroni; Alexey Sokolovskiy; Camilla Tøndel; Einar Svarstad; Bogdan Obrisca; Gener Ismail; Myrl D Holida; Michael Mauer
Journal:  Kidney Int       Date:  2022-04-26       Impact factor: 18.998

2.  The Patients' Experiences of Burden of Neurofibromatosis: A Qualitative Study.

Authors:  Samira Foji; Eesa Mohammadi; Akram Sanagoo; Leila Jouybari
Journal:  Iran J Nurs Midwifery Res       Date:  2021-07-20

Review 3.  Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review.

Authors:  Louise L C Pinto; Taiane A Vieira; Roberto Giugliani; Ida V D Schwartz
Journal:  Orphanet J Rare Dis       Date:  2010-05-28       Impact factor: 4.123

4.  The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations.

Authors:  Helena Poupetová; Jana Ledvinová; Linda Berná; Lenka Dvoráková; Viktor Kozich; Milan Elleder
Journal:  J Inherit Metab Dis       Date:  2010-05-20       Impact factor: 4.982

5.  Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors.

Authors:  Dawn A Laney; Robin L Bennett; Virginia Clarke; Angela Fox; Robert J Hopkin; Jack Johnson; Erin O'Rourke; Katherine Sims; Gerald Walter
Journal:  J Genet Couns       Date:  2013-07-17       Impact factor: 2.537

6.  Experiences of Being Heterozygous for Fabry Disease: a Qualitative Study.

Authors:  Charlotte von der Lippe; Jan C Frich; Anna Harris; Kari Nyheim Solbrække
Journal:  J Genet Couns       Date:  2016-03-07       Impact factor: 2.537

7.  Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease.

Authors:  Michael Mauer; Emily Glynn; Einar Svarstad; Camilla Tøndel; Marie-Claire Gubler; Michael West; Alexey Sokolovskiy; Chester Whitley; Behzad Najafian
Journal:  PLoS One       Date:  2014-11-11       Impact factor: 3.240

8.  Gender Differences in the Application of Spanish Criteria for Initiation of Enzyme Replacement Therapy for Fabry Disease in the Fabry Outcome Survey.

Authors:  Miguel-Ángel Barba-Romero; Guillem Pintos-Morell
Journal:  Int J Mol Sci       Date:  2016-11-24       Impact factor: 5.923

Review 9.  Living with a rare disorder: a systematic review of the qualitative literature.

Authors:  Charlotte von der Lippe; Plata S Diesen; Kristin B Feragen
Journal:  Mol Genet Genomic Med       Date:  2017-07-23       Impact factor: 2.183

10.  The Effect of Green Tea as an Adjuvant to Enzyme Replacement Therapy on Oxidative Stress in Fabry Disease: A Pilot Study.

Authors:  Giovanni Bertoldi; Gianni Carraro; Verdiana Ravarotto; Valentina Di Vico; Paola Baldini Anastasio; Nicola Vitturi; Francesco Francini; Lucia Federica Stefanelli; Lorenzo A Calò
Journal:  Front Nutr       Date:  2022-07-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.